- Home
- KSS vs JANX Comparison
KSS vs JANX Comparison
Compare KSS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KSS
- JANX
- Stock Information
- Founded
- KSS 1962
- JANX 2017
- Country
- KSS United States
- JANX United States
- Employees
- KSS N/A
- JANX N/A
- Industry
- KSS Department/Specialty Retail Stores
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- KSS Consumer Discretionary
- JANX Health Care
- Exchange
- KSS Nasdaq
- JANX Nasdaq
- Market Cap
- KSS 1.4B
- JANX 1.6B
- IPO Year
- KSS 1992
- JANX 2021
- Fundamental
- Price
- KSS $7.10
- JANX $26.02
- Analyst Decision
- KSS Sell
- JANX Strong Buy
- Analyst Count
- KSS 13
- JANX 7
- Target Price
- KSS $8.13
- JANX $94.29
- AVG Volume (30 Days)
- KSS 10.8M
- JANX 974.6K
- Earning Date
- KSS 05-29-2025
- JANX 05-20-2025
- Dividend Yield
- KSS 23.02%
- JANX N/A
- EPS Growth
- KSS N/A
- JANX N/A
- EPS
- KSS 0.98
- JANX N/A
- Revenue
- KSS $16,221,000,000.00
- JANX $10,588,000.00
- Revenue This Year
- KSS N/A
- JANX N/A
- Revenue Next Year
- KSS N/A
- JANX $250.58
- P/E Ratio
- KSS $7.20
- JANX N/A
- Revenue Growth
- KSS N/A
- JANX 30.99
- 52 Week Low
- KSS $6.04
- JANX $22.52
- 52 Week High
- KSS $28.25
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- KSS 48.38
- JANX 41.70
- Support Level
- KSS $6.47
- JANX $24.13
- Resistance Level
- KSS $7.65
- JANX $33.97
- Average True Range (ATR)
- KSS 0.40
- JANX 1.93
- MACD
- KSS 0.13
- JANX -0.51
- Stochastic Oscillator
- KSS 59.06
- JANX 29.57
About KSS Kohl's Corporation
Kohl's operates about 1,176 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 26% of its 2023 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.